Weight loss associated with semaglutide treatment among people with HIV
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: There is limited real-world evidence about the effectiveness of semaglutide for weight loss among people with HIV (PWH). We aimed to investigate weight change in a US cohort of PWH who initiated semaglutide treatment.
DESIGN: Observational study using the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort.
METHODS: We identified adult PWH who initiated semaglutide between 2018 and 2022 and with at least two weight measurements. The primary outcome was within-person bodyweight change in kilograms at 1 year. The secondary outcome was within-person Hemoglobin A1c percentage (HbA1c) change. Both outcomes were estimated using multivariable linear mixed model.
RESULTS: In total, 222 new users of semaglutide met inclusion criteria. Mean follow-up was 1.1 years. Approximately 75% of new semaglutide users were men, and at baseline, mean age was 53 years [standard deviation (SD): 10], average weight was 108 kg (SD: 23), mean BMI was 35.5 kg/m 2 , mean HbA1c was 7.7% and 77% had clinically recognized diabetes. At baseline, 97% were on ART and 89% were virally suppressed (viral load < 50 copies/ml). In the adjusted mixed model analysis, treatment with semaglutide was associated with an average weight loss of 6.47 kg at 1 year (95% CI -7.67 to -5.18) and with a reduction in HbA1c of 1.07% at 1 year (95% CI -1.64 to -0.50) among the 157 PWH with a postindex HbA1c value.
CONCLUSION: Semaglutide was associated with significant weight loss and HbA1c reduction among PWH, comparable to results of previous studies from the general population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
AIDS (London, England) - 38(2024), 4 vom: 15. März, Seite 531-535 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haidar, Lara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
53AXN4NNHX |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 10.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAD.0000000000003791 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364675942 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364675942 | ||
| 003 | DE-627 | ||
| 005 | 20240310231859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAD.0000000000003791 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1322.xml |
| 035 | |a (DE-627)NLM364675942 | ||
| 035 | |a (NLM)37976053 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Haidar, Lara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Weight loss associated with semaglutide treatment among people with HIV |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 10.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: There is limited real-world evidence about the effectiveness of semaglutide for weight loss among people with HIV (PWH). We aimed to investigate weight change in a US cohort of PWH who initiated semaglutide treatment | ||
| 520 | |a DESIGN: Observational study using the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort | ||
| 520 | |a METHODS: We identified adult PWH who initiated semaglutide between 2018 and 2022 and with at least two weight measurements. The primary outcome was within-person bodyweight change in kilograms at 1 year. The secondary outcome was within-person Hemoglobin A1c percentage (HbA1c) change. Both outcomes were estimated using multivariable linear mixed model | ||
| 520 | |a RESULTS: In total, 222 new users of semaglutide met inclusion criteria. Mean follow-up was 1.1 years. Approximately 75% of new semaglutide users were men, and at baseline, mean age was 53 years [standard deviation (SD): 10], average weight was 108 kg (SD: 23), mean BMI was 35.5 kg/m 2 , mean HbA1c was 7.7% and 77% had clinically recognized diabetes. At baseline, 97% were on ART and 89% were virally suppressed (viral load < 50 copies/ml). In the adjusted mixed model analysis, treatment with semaglutide was associated with an average weight loss of 6.47 kg at 1 year (95% CI -7.67 to -5.18) and with a reduction in HbA1c of 1.07% at 1 year (95% CI -1.64 to -0.50) among the 157 PWH with a postindex HbA1c value | ||
| 520 | |a CONCLUSION: Semaglutide was associated with significant weight loss and HbA1c reduction among PWH, comparable to results of previous studies from the general population | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a semaglutide |2 NLM | |
| 650 | 7 | |a 53AXN4NNHX |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptides |2 NLM | |
| 650 | 7 | |a 62340-29-8 |2 NLM | |
| 700 | 1 | |a Crane, Heidi M |e verfasserin |4 aut | |
| 700 | 1 | |a Nance, Robin M |e verfasserin |4 aut | |
| 700 | 1 | |a Webel, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Ruderman, Stephanie A |e verfasserin |4 aut | |
| 700 | 1 | |a Whitney, Bridget M |e verfasserin |4 aut | |
| 700 | 1 | |a Willig, Amanda L |e verfasserin |4 aut | |
| 700 | 1 | |a Napravnik, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Mixson, L Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Leong, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Lavu, Alekhya |e verfasserin |4 aut | |
| 700 | 1 | |a Aboulatta, Laila |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Mindy |e verfasserin |4 aut | |
| 700 | 1 | |a Hahn, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Saag, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Bamford, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Cachay, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Kitahata, Mari M |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Kenneth H |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobson, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Delaney, Joseph A C |e verfasserin |4 aut | |
| 700 | 1 | |a Drumright, Lydia N |e verfasserin |4 aut | |
| 700 | 1 | |a Eltonsy, Sherif |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 38(2024), 4 vom: 15. März, Seite 531-535 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:531-535 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000003791 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 4 |b 15 |c 03 |h 531-535 | ||